Tengshengboyao-B (02137) surged by more than 9% in late trading

　　Tengshengbo medicine-B(02137) It surged by more than 9% in late trading, and it has risen by more than 165% in the past three weeks. As of press time, it has risen 9.35% to 47.95 Hong Kong dollars, with a turnover of 111 million Hong Kong dollars.

On the news, the new South African strain B.1.1.529 has attracted widespread market attention. According to reports, this mutant strain has accounted for 90% of all domestic variants in South Africa in just 20 days, far exceeding the initial increase in Delta and Beta outbreaks. speed. The WHO named the strain Omicron (奥米克荣) and stated that the overall global risk associated with the Omicron mutant strain was assessed as “very high.” The news stimulated funds to pay attention to the new crown drug stocks.

It is reported that there have been media reports that the new crown drug BRII-196 and BRII-198 jointly developed by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Bo Pharmaceutical has been unblinded in clinical phase III, and the drug delivery group will be realized after 28 days of treatment. There were zero deaths and 8 deaths in the control group. The detailed results will be announced in the near future. This is also the fastest-growing antibody drug in my country, and it is expected to be approved for conditional listing before the end of December. Compared with the new coronavirus antibody drug that has been approved for emergency use in Europe and the United States, this drug is the only one that has evaluated and obtained data on the treatment effect of patients infected with variant strains.

(Source: Zhitong Finance Network)

Article source: Zhitong Finance Network

Editor in charge: 33

Original title: Hong Kong stocks move | Tengsheng Biopharmaceuticals-B (02137) surged more than 9% in late trading